Niedrig dosierte Fumarsäureester-Langzeittherapie bei behandlungsresistenter kutaner Sarkoidose

Breuer K, Gutzmer R, Völker B, Kapp A, Werfel T (2005) Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 152:1290–1295

Dai D, Shih S, Ansari A, Kwak Y, Sami N (2019) Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review. Am J Clin Dermatol 20:409–422

Gieselbach RJ, Muller-Hansma AH, Wijburg MT et al (2017) Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264:1155–1164

Gold R, Linker RA, Stangel M (2012) Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 142:44–48

Gutzmer R, Kapp A, Werfel T (2004) Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumarsäureestern. Hautarzt 55:553–557

Hoyer P, Scharf S, Danneberg R, Kroll H, Zouboulis CC, Lippert U (2013) Mechanisms of fumaric acid ester action on granuloma formation. Exp Dermatol 22:e36

Lianos O, Hamzeh N (2019) Sarcoidosis. Med Clin North Am 103:527–534

Miura T, Kikuchi N, Yamamoto T (2020) Cutaneous sarcoidosis in 95 Japanese patients: a single institutional study. Eur J Dermatol. https://doi.org/10.1684/ejd.2020.3745

Nowack U, Gambichler T, Hanefeld C, Kastner U, Altmeyer P (2002) Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2:15

Rolls S, Porter W (2018) Oral Fumaderm® to treat cutaneous sarcoidosis. Clin Exp Dermatol 43:611–613

Rubant SA, Ludwig RJ, Diehl S, Hardt K, Kaufmann R, Pfeilschifter JM, Boehncke WH (2008) Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 128:326–331

Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer’s response to case reports of PML. N Engl J Med 368:1659–1661

Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL‑6 in an in-vitro model of brain inflammation. J Neuroinflammation 7:30

Wolter A, Müller M, Völker B, Gehring M, Caldarone F, Kapp A, Werfel T, Raap U (2012) Kutane und pulmonale Sarkoidose – Erfolgreiche Therapie mit Fumarsäureestern. Hautarzt 63:808–812

Zhu K, Mrowietz U (2001) Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 116:203–208

Zouboulis CC, Lippert U, Karagiannidis I (2014) Multi-organ sarcoidosis treatment with fumaric acid esters: a case report and review of the literature. Dermatology 228:202–206